1990—2021年中国归因于高LDL-C的卒中死亡负担变化趋势及预测分析

doi:10.3969/j.issn.1673-5765.2025.04.008

摘要/Abstract

摘要： 目的分析1990—2021年中国归因于高LDL-C的卒中死亡负担变化趋势，探讨年龄、时期、队列因素的影响，并预测未来死亡负担变化。
方法基于2021年全球疾病负担数据库中1990—2021年中国≥20岁人群归因于高LDL-C的卒中死亡负担数据，运用Joinpoint回归模型分析年龄标化死亡率随时间的变化趋势，通过年龄-时期-队列模型估算中国归因于高LDL-C的卒中死亡率的年龄、时期和队列效应，使用整合移动平均自回归（autoregressive integrated moving average，ARIMA）模型预测2022—2030年中国归因于高LDL-C的卒中死亡负担。
结果相较于1990年，2021年中国归因于高LDL-C的卒中死亡数、死亡率均明显增长，年龄标化死亡率有所下降。2021年全人群、男性和女性死亡数分别为30.01万例、17.05万例和12.95万例，较1990年分别升高161.87%、187.04%和134.60%；2021年全人群、男性和女性死亡率分别为21.08/10万、23.42/10万和18.64/10万，较1990年分别升高116.65%、139.22%和92.56%；2021年全人群、男性和女性年龄标化死亡率分别为15.93/10万、20.96/10万和12.36/10万，年度变化百分比估计值分别为-0.43%、-0.02%和-0.88%（均P＜0.05）。Joinpoint回归模型分析结果显示，1990—2021年中国归因于高LDL-C的卒中年龄标化死亡率整体呈先升后降趋势，且男性的年龄标化死亡率高于女性。年龄-时期-队列模型分析结果显示，归因于高LDL-C的卒中死亡率总体上随年龄的增长而增加，全人群、男性、女性的RR变化范围分别为0.028～12.214、0.027～14.661和0.032～15.258；随时期推移呈上升趋势，全人群、男性、女性RR变化范围分别为0.677～1.418、0.623～1.532和0.750～1.298；总体上随着队列变化呈下降趋势，全人群、男性、女性RR变化范围分别为0.213～4.210、0.221～3.637和0.170～3.978。ARIMA模型预测结果显示，2022—2030年中国归因于高LDL-C的全人群、男性和女性卒中死亡数和死亡率将持续升高，男性年龄标化死亡率将呈上升趋势，但全人群和女性的年龄标化死亡率将保持稳定。
结论 1990—2021年，中国归因于高LDL-C的卒中死亡负担呈上升趋势，且男性的死亡负担重于女性。死亡率整体上随年龄的增长而增加，随时期的推移而增长，随出生队列的变化而降低。预计未来一段时间内死亡负担仍将持续加重。

文章导读： 1990—2021年中国归因于高LDL-C的卒中死亡负担整体呈上升趋势，男性负担重于女性，但年龄标化死亡率略有下降。年龄、时期和队列因素对死亡率影响显著，预计未来负担仍会持续加重。

关键词: 卒中; 低密度脂蛋白胆固醇; 全球疾病负担; Joinpoint回归; 年龄-时期-队列模型

Abstract: Objective To analyze the trends in the burden of stroke deaths attributable to high LDL-C in China from 1990 to 2021, explore the effects of age, period, and cohort factors, and predict the future changes in the burden of death.
Methods Using the data from the global burden of disease database 2021 on stroke deaths attributable to high LDL-C in Chinese adults aged≥20 years from 1990 to 2021, the Joinpoint regression model was used to analyze the trends of age-standardized death rates over time. Through the age-period-cohort model, the age, period, and cohort effects of stroke deaths attributable to high LDL-C in China were estimated. The autoregressive integrated moving average (ARIMA) model was used to predict the burden of stroke deaths attributable to high LDL-C in China from 2022 to 2030.
Results Compared with 1990, the number and rate of stroke deaths attributable to high LDL-C in China have significantly increased in 2021, while the age-standardized death rates has decreased. In 2021, the total number of deaths for the whole population, males, and females were 300 100, 170 500, and 129 500, respectively, which were 161.87%, 187.04%, and 134.60% higher than those in 1990. The mortality rates in 2021 were 21.08/100 000, 23.42/100 000, and 18.64/100 000, respectively, which were 116.65%, 139.22%, and 92.56% higher than those in 1990. The age-standardized death rates in 2021 were 15.93/100 000, 20.96/100 000, and 12.36/100 000, with estimated annual percentage changes of -0.43%, -0.02%, and -0.88%, respectively (all P<0.05). The results of the Joinpoint regression model showed that from 1990 to 2021, the age-standardized death rates of stroke attributable to high LDL-C in China showed a trend of first increasing and then decreasing in general, and the age-standardized death rates were higher in males than in females. The results of the age-period-cohort model analysis showed that the stroke mortality rates attributable to high LDL-C generally increased with age, with RR ranging from 0.028 to 12.214 in the whole population, 0.027 to 14.661 in males, and 0.032 to 15.258 in females. The period effect showed an increasing trend, with RR ranging from 0.677 to 1.418 in the whole population, 0.623 to 1.532 in males, and 0.750 to 1.298 in females. The cohort effect showed a decreasing trend, with RR ranging from 0.213 to 4.210 in the whole population, 0.221 to 3.637 in males, and 0.170 to 3.978 in females. The results of the ARIMA model predicted that from 2022 to 2030, the number and rate of stroke deaths attributable to high LDL-C in China’s whole population, males, and females will continue to rise. The age-standardized death rates for males will show an increasing trend, but the age-standardized death rates for the whole population and females will remain steady.
Conclusions From 1990 to 2021, the burden of stroke deaths attributable to high LDL-C has been increasing in China, and the burden of death is heavier in males than in females. Mortality increases with age, grows over periods, and decreases by birth cohorts. The burden of death is expected to remain heavy for the foreseeable future.

Key words: Stroke; Low density lipoprotein cholesterol; Global burden of disease; Joinpoint regression; Age-period-cohort model

中图分类号:

张永庆, 李娜, 高伊丽, 秦佳文, 俞海萍, 赵婷婷. 1990—2021年中国归因于高LDL-C的卒中死亡负担变化趋势及预测分析[J]. 中国卒中杂志, 2025, 20(4): 447-456.

ZHANG Yongqing, LI Na, GAO Yili, QIN Jiawen, YU Haiping, ZHAO Tingting. Trends and Predictive Analysis of the Burden of Stroke Deaths Attributable to High LDL-C in China from 1990 to 2021[J]. Chinese Journal of Stroke, 2025, 20(4): 447-456.

参考文献

[1] SAINI V，GUADA L，YAVAGAL D R. Global epidemiology of stroke and access to acute ischemic stroke interventions[J/OL]. Neurology，2021，97（20_Supplement_2）：S6-S16[2024-09-18]. https://doi.org/10.1212/WNL.0000000000012781.
[2] TU W J，ZHAO Z P，YIN P，et al. Estimated burden of stroke in China in 2020[J/OL]. JAMA Netw Open，2023，6（3）：e231455[2024-09-18]. https://doi.org/10.1001/jamanetworkopen.2023.1455.
[3] PAN Y S，WANG Q R，LI H，et al. LDL-C levels，lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA[J]. Stroke Vasc Neurol，2022，7（4）：276-284.
[4] Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age，sex，and blood pressure：a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths[J]. Lancet，2007，370（9602）：1829-1839.
[5] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（2023年）[J]. 中国循环杂志，2023，38（3）：237-271.
Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guidelines for lipid management（2023）[J]. Chinese Circulation Journal，2023，38（3）：237-271.
[6] ZHANG J，ZHU S J，LIU C L，et al. Global，regional and national burden of ischemic stroke attributed to high low-density lipoprotein cholesterol，1990—2019：a decomposition analysis and age-period-cohort analysis[J]. J Cereb Blood Flow Metab，2024，44（4）：527-541.
[7] IORIO R. The future is here：bundled payments and international statistical classification of diseases，10th revision[J/OL]. J Arthroplasty，2016，31（5）：931[2024-09-18]. https://doi.org/10.1016/j.arth.2016.02.040.
[8] 徐晓慧，杨静，王黎君，等. 2017年中国人群高血清低密度脂蛋白胆固醇归因疾病负担研究[J]. 中华流行病学杂志，2020，41（6）：839-844.
XU X H，YANG J，WANG L J，et al. Burden of disease attributed to high level serum low-density lipoprotein cholesterol in China in 2017[J]. Chin J Epidemiol，2020，41（6）：839-844.
[9] 屈彦，王天一，杨津，等. GBD数据库的数据提取方法与流程[J]. 中国循证心血管医学杂志，2019，11（9）：1043-1046.
QU Y，WANG T Y，YANG J，et al. GBD database application and data extraction methods and processes[J]. Chin J Evid Based Cardiovasc Med，2019，11（9）：1043-1046.
[10] 陈悦，沈婉莹，陈磊，等. 基于年龄-时期-队列模型分析1990—2019年中国肝癌发病趋势[J]. 中国预防医学杂志，2021，22（5）：329-335.
CHEN Y，SHEN W Y，CHEN L，et al. Trend of liver cancer incidence in China from 1990 to 2019 analyzed using the age-period-cohort model[J]. Chin Prev Med，2021，22（5）：329-335.
[11] 袁空军，杨媛，赵创艺，等. 1990—2019年中国高血清低密度脂蛋白胆固醇疾病负担趋势分析与预测[J]. 现代预防医学，2022，49（14）：2502-2509.
YUAN K J，YANG Y，ZHAO C Y，et al. Trend analysis and prediction of disease burden of high level serum low-density lipoprotein cholesterol in China from 1990 to 2019[J]. Modern Preventive Medicine，2022，49（14）：2502-2509.
[12] 袁空军，赵创艺，杨媛，等. 中国人群1990—2019年高低密度脂蛋白胆固醇归因疾病负担趋势分析[J]. 中国循证医学杂志，2022，22（4）：444-449.
YUAN K J，ZHAO C Y，YANG Y，et al. Burden trend analysis of disease attributable to high low density lipoprotein cholesterol in Chinese population from 1990 to 2019[J]. Chinese Journal of Evidence-Based Medicine，2022，22（4）：444-449.
[13] 邬林果，武荣伟，杨德刚. 2000—2020年中国人口老龄化时空演变及影响因素研究[J]. 世界地理研究，2024，33（5）：163-176.
WU L G，WU R W，YANG D G. Spatial-temporal patterns and influencing factors of population aging in China from 2000 to 2020[J]. World Regional Studies，2024，33（5）：163-176.
[14] LEE H，NAM Y S，LEE K M. Development-assistance strategies for stroke in low- and middle-income countries[J/OL]. J Korean Med Sci，2015，30（Suppl 2）：S139-S142[2024-09-18]. https://doi.org/10.3346/jkms.2015.30.S2.S139.
[15] 陆杰华，张宇昕. 基于性别公平视角的中国老龄公共政策评估探究[J]. 河北学刊，2023，43（6）：145-154.
LU J H，ZHANG Y X. Evaluation of public policy on aging in China from the perspective of gender equity[J]. Hebei Academic Journal，2023，43（6）：145-154.
[16] 任泽平. 中国老龄化报告[J]. 发展研究，2023，40（2）：22-30.
REN Z P. China’s aging report[J]. Development Research，2023，40（2）：22-30.
[17] 唐春花，郭露，李琼，等. 2022年全球卒中数据报告解读[J]. 诊断学理论与实践，2023，22（3）：238-246.
TANG C H，GUO L，LI Q，et al. Interpretation on the report of global stroke data 2022[J]. J Diagn Concepts Pract，2023，22（3）：238-246.
[18] 汤少梁，赵兴华，董慧秋，等. 中国、美国和全球居民2010—2019年脑卒中疾病负担趋势年龄–时期–队列分析[J]. 中国公共卫生，2024，40（6）：649-658.
TANG S L，ZHAO X H，DONG H Q，et al. Changing trends in burden of stroke among residents of China，the United States，and the world during 2010—2019：an age-period-cohort analysis of data from GBD 2019[J]. Chin J Public Health，2024，40（6）：649-658.
[19] 朱广涵，刘雪薇，韦丹梅，等. 1990—2019年中国结直肠癌发病与死亡趋势的APC模型分析[J]. 中国卫生统计，2024，41（2）：218-222.
ZHU G H，LIU X W，WEI D M，et al. APC model analysis of trends in incidence and mortality of colorectal cancer in China，1990—2019[J]. Chinese Journal of Health Statistics，2024，41（2）：218-222.
[20] GBD 2021 Diseases and Injuries Collaborators. Global incidence，prevalence，years lived with disability（YLDs），disability-adjusted life-years（DALYs），and healthy life expectancy（HALE）for 371 diseases and injuries in 204 countries and territories and 811 subnational locations，1990—2021：a systematic analysis for the global burden of disease study 2021[J]. Lancet，2024，403（10440）：2133-2161.
[21] 陈晓荣，颜流霞，厚磊，等. 2015—2019年中国居民脑卒中发病与死亡特征分析[J]. 中国循环杂志，2024，39（5）：470-476.
CHEN X R，YAN L X，HOU L，et al. Trends of stroke incidence and mortality from 2015 to 2019 in China[J]. Chinese Circulation Journal，2024，39（5）：470-476.
[22] PENCINA M J，PENCINA K M，LLOYD-JONES D，et al. The expected 30-year benefits of early versus delayed primary prevention of cardiovascular disease by lipid lowering[J]. Circulation，2020，142（9）：827-837.
[23] MACH F，BAIGENT C，CATAPANO A L，et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias：lipid modification to reduce cardiovascular risk[J]. Eur Heart J，2020，41（1）：111-188.
[24] 高莹，窦克非，高润霖. 加强我国基层血脂管理刻不容缓[J]. 中国循环杂志，2022，37（3）：209-211.
GAO Y，DOU K F，GAO R L. Strengthening lipid management at the grassroots level in China is a matter of urgency[J]. Chinese Circulation Journal，2022，37（3）：209-211.